64. Thrombotic thrombocytopenic purpura
74 clinical trials,   76 drugs   (DrugBank: 19 drugs),   15 drug target genes,   57 drug target pathways

Searched query = "Thrombotic thrombocytopenic purpura", "TTP", "Upshaw-Schulman syndrome", "USS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-001117-86-GB
(EUCTR)
25/07/201718/05/2018Elective rituximab in TTPA phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP - Elective rituximab in TTP Acquired thrombotic thrombocytopenic purpura;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]Trade Name: Mabthera
Product Name: Mabthera
University College LondonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
52Phase 4United Kingdom
2EUCTR2010-018794-38-IT
(EUCTR)
23/02/201026/07/2010EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPEVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTP THROMBOTIC THROMBOCYTOPENIC PURPURA
MedDRA version: 9.1;Level: LLT;Classification code 10037562
Trade Name: MABTHERA
INN or Proposed INN: Rituximab
FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
3NCT00937131
(ClinicalTrials.gov)
March 20069/7/2009The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)A Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) in Combination With Plasma Exchange (PEX) in Patients With Acute Thrombotic Thrombocytopenic Purpura (TTP)Thrombotic Thrombocytopenic Purpura (TTP)Drug: RituximabUniversity College, LondonNULLActive, not recruiting18 Years65 YearsBoth40Phase 2United Kingdom
4EUCTR2005-002274-30-GB
(EUCTR)
14/12/200504/11/2005A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. - The use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura.A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. - The use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura. Thrombotic Thrombocytopenia PurpuraUniversity College LondonNULLNot Recruiting Female: yes
Male: yes
40Phase 2United Kingdom